Lack of the T cell-specific alternative p38 activation pathway reduces autoimmunity and inflammation

Blood

Volumn 118, Issue 12, 2011, Pages 3280-3289

  Jirmanova, Ludmila ^a   Torchia, Maria Letizia Giardino ^a   Sarma, Nandakumara D ^a   Mittelstadt, Paul R ^a   Ashwell, Jonathan D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; GAMMA INTERFERON; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45 ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 11; MITOGEN ACTIVATED PROTEIN KINASE 14; PHENYLALANINE; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR T BET; TUMOR NECROSIS FACTOR ALPHA; TYROSINE; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; CELL PROLIFERATION; CYTOKINE PRODUCTION; DISEASE SEVERITY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL;

EID: 80053196380     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-333039     Document Type: Article

References (45)

1. Ashwell JD. The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nat Rev Immunol. 2006;6(7):532-540. (Pubitemid 43980525)
2. Li Z, Jiang Y, Ulevitch RJ, Han J. The primary structure of p38 gamma: a new member of p38 group of MAP kinases. Biochem Biophys Res Commun. 1996;228(2):334-340. (Pubitemid 26396075)
3. Jiang Y, Chen C, Li Z, et al. Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem. 1996;271(30):17920-17926. (Pubitemid 26250772)
4. Diskin R, Askari N, Capone R, Engelberg D, Livnah O. Active mutants of the human p38alpha mitogen-activated protein kinase. J Biol Chem. 2004;279(45):47040-47049. (Pubitemid 39518359)
5. Enslen H, Raingeaud J, Davis RJ. Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. J Biol Chem. 1998;273(3):1741-1748. (Pubitemid 28133705)
6. Mittelstadt PR, Yamaguchi H, Appella E, Ashwell JD. T cell receptor-mediated activation of p38alpha by mono-phosphorylation of the activation loop results in altered substrate specificity. J Biol Chem. 2009;284(23):15469-15474.
7. Salvador JM, Mittelstadt PR, Guszczynski T, et al. Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases. Nat Immunol. 2005;6(4):390-395. (Pubitemid 41716779)
8. Jirmanova L, Sarma DN, Jankovic D, Mittelstadt PR, Ashwell JD. Genetic disruption of p38alpha Tyr323 phosphorylation prevents T-cell receptor-mediated p38alpha activation and impairs interferon-gamma production. Blood. 2009;113(10):2229-2237.
9. Salvador JM, Hollander MC, Nguyen AT, et al. Mice lacking the p53-effector gene Gadd45a develop a lupus-like syndrome. Immunity. 2002;16(4):499-508. (Pubitemid 34442575)
10. Salvador JM, Mittelstadt PR, Belova GI, Fornace AJJ, Ashwell JD. The autoimmune suppressor Gadd45alpha inhibits the T cell alternative p38 activation pathway. Nat Immunol. 2005;6(4):396-402. (Pubitemid 41716780)
11. Takekawa M, Saito H. A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell. 1998;95(4):521-530. (Pubitemid 28533308)
12. Jirmanova L, Jankovic D, Fornace AJJ, Ashwell JD. Gadd45alpha regulates p38-dependent dendritic cell cytokine production and Th1 differentiation. J Immunol. 2007;178(7):4153-4158. (Pubitemid 46492365)
13. Hildesheim J, Bulavin DV, Anver MR, et al. Gadd45a protects against UV irradiation-induced skin tumors, and promotes apoptosis and stress signaling via MAPK and p53. Cancer Res. 2002;62(24):7305-7315. (Pubitemid 36025254)
14. Murciano C, Villamon E, Yanez A, O'Connor JE, Gozalbo D, Gil ML. Impaired immune response to Candida albicans in aged mice. J Med Microbiol. 2006;55(12):1649-1656. (Pubitemid 44902027)
15. Hamdi H, Mariette X, Godot V, et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther. 2006;8(4):R114.
16. Elenkov IJ. Glucocorticoids and the Th1/Th2 balance. Ann N Y Acad Sci. 2004;1024:138-146. (Pubitemid 38879598)
17. Oncel C, Baser S, Cam M, Akdag B, Taspinar B, Evyapan F. Peripheral neuropathy in chronic obstructive pulmonary disease. COPD. 2010;7(1):11-16.
18. Bingham CO III. The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation. J Rheumatol Suppl. 2002;65:3-9.
19. Murphy AC, Lalor SJ, Lynch MA, Mills KH. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun. 2010;24(4):641-651.
20. Hofstetter HH, Forsthuber TG. Kinetics of IL- 17-and interferon-gamma- producing PLPp-specific CD4 T cells in EAE induced by coinjection of PLPp/IFA with pertussis toxin in SJL mice. Neurosci Lett. 2010;476(3):150-155.
21. Shin T, Ahn M, Jung K, et al. Activation of mitogen-activated protein kinases in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2003;140(1):118-125. (Pubitemid 36840905)
22. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther. 1996;279(3):1453-1461. (Pubitemid 27166795)
23. Montalban AG, Boman E, Chang CD, et al. KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. Eur J Pharmacol. 2010;632(1):93-102.
24. Hollander MC, Sheikh MS, Bulavin DV, et al. Genomic instability in Gadd45a-deficient mice. Nat Genet. 1999;23(2):176-184. (Pubitemid 29455389)
25. Frey A, Di Canzio J, Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods. 1998;221(1):35-41. (Pubitemid 29017921)
26. Hale KK, Trollinger D, Rihanek M, Manthey CL. Differential expression and activation of p38 mitogen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages. J Immunol. 1999;162(7):4246-4252. (Pubitemid 29314814)
27. Hwang ES, Szabo SJ, Schwartzberg PL, Glimcher LH. T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3. Science. 2005;307(5708):430-433. (Pubitemid 40139989)
28. Li YY, Bao M, Meurer J, et al. The identification of a small molecule inhibitor that specifically reduces T cell-mediated adaptive but not LPS-mediated innate immunity by T cell membrane-monocyte contact bioassay. Immunol Lett. 2008;117(1):114-118.
29. Kebir H, Ifergan I, Alvarez JI, et al. Preferential recruitment of interferon-gamma-expressing T H 17 cells in multiple sclerosis. Ann Neurol. 2009;66(3):390-402.
30. Bygrave AE, Rose KL, Cortes-Hernandez J, et al. Spontaneous autoimmunity in 129 and C57BL/6 mice-implications for autoimmunity described in gene-targeted mice. PLoS Biol. 2004;2(8):E243.
31. Hoshino K, Sugiyama T, Matsumoto M, et al. IkappaB kinase-alpha is critical for interferon-alpha production induced by Toll-like receptors 7 and 9. Nature. 2006;440(7086):949-953.
32. Pont-Giralt M, Godessart N, Balague C. Differential pharmacological behaviour of p38 inhibitors in regulating the LPS-induced TNF-alpha production in human and rat whole blood in vitro. Inflammation. 2010;34(2):119-132.
33. Yun HJ, Yoo WH, Han MK, Lee YR, Kim JS, Lee SI. Epigallocatechin-3- gallate suppresses TNF-alpha-induced production of MMP-1 and -3 in rheumatoid arthritis synovial fibroblasts. Rheumatol Int. 2008;29(1):23-29.
34. Myers LK, Miyahara H, Terato K, Seyer JM, Stuart JM, Kang AH. Collagen-induced arthritis in B10.RIII mice (H-2r): identification of an arthritogenic T-cell determinant. Immunology. 1995;84(4):509-513.
35. Adams RH, Porras A, Alonso G, et al. Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development. Mol Cell. 2000;6(1):109-116.
36. Berenson LS, Yang J, Sleckman BP, Murphy TL, Murphy KM. Selective requirement of p38alpha MAPK in cytokine-dependent, but not antigen receptor-dependent, Th1 responses. J Immunol. 2006;176(8):4616-4621.
37. Beardmore VA, Hinton HJ, Eftychi C, et al. Generation and characterization of p38beta (MAPK11) gene-targeted mice. Mol Cell Biol. 2005;25(23):10454-10464. (Pubitemid 41681967)
38. Nikoopour E, Schwartz JA, Singh B. Therapeutic benefits of regulating inflammation in autoimmunity. Inflamm Allergy Drug Targets. 2008;7(3):203-210.
39. Atzeni F, Sarzi-Puttini P. Anti-cytokine antibodies for rheumatic diseases. Curr Opin Investig Drugs. 2009;10(11):1204-1211.
40. Singh D, Smyth L, Borrill Z, Sweeney L, Tal-Singer R. A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. J Clin Pharmacol. 2010;50(1):94-100.
41. Alten RE, Zerbini C, Jeka S, et al. Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy. Ann Rheum Dis. 2010;69(2):364-367.
42. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009;60(5):1232-1241.
43. Cohen S, Fleischmann R. Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr Opin Rheumatol. 2010;22(3):330-335.
44. Noel JK, Crean S, Claflin JE, Ranganathan G, Linz H, Lahn M. Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 mitogen-activated protein kinases for treatment of cancer: a systematic review of the literature. Med Oncol. 2008;25(3):323-330.
45. Zhang J, Shen B, Lin A. Novel strategies for inhibition of the p38 MAPK pathway. Trends Pharmacol Sci. 2007;28(6):286-295. (Pubitemid 46818466)